Sareum allowed European patent for primary kinase inhibitor asset
15th Mar 2024 13:11
(Sharecast News) - Biotechnology company Sareum announced on Friday that the European Patent Office had issued a notice of allowance for a patent concerning SDC‐1801, its primary TYK2/JAK1 kinase inhibitor currently undergoing clinical trials in Australia.
Read moreSareum reports positive progress in psoriasis programme
15th Feb 2024 13:22
(Sharecast News) - Sareum announced significant milestones in its phase 1a clinical trial for SDC-1801, its lead programme aimed at addressing autoimmune diseases such as psoriasis, on Thursday.
Read moreSareum shares jump on cancer drug licensing deal
2nd Jan 2024 13:54
(Sharecast News) - Shares in AIM-listed biotech group Sareum jumped by a fifth on Tuesday after its co-development partner for cancer treatment SRA737 signed a commercialisation licence agreement with a US biopharma company.
Read moreSareum secures Japan patent for kinase inhibitor asset
3rd Nov 2023 13:59
(Sharecast News) - Biotechnology firm Sareum announced on Friday that it has received a notice of allowance from the Japan Patent Office for a patent associated with SDC-1801, its primary TYK2/JAK1 kinase inhibitor.
Read moreSareum losses widen as clinical trials continue
9th Oct 2023 15:06
(Sharecast News) - Biotechnology company Sareum Holdings reported a loss of £3.2m after tax in its final results on Monday, widening from last year's £2.2m due to heightened expenses from initiating clinical studies with SDC-1801, despite aligning with market anticipations.
Read moreDirector dealings: Blackbird, Sareum insiders pick up shares
6th Sep 2023 14:35
(Sharecast News) - Blackbird found itself with a number of entries on the list of director buys on Wednesday, after a number of insiders and associates bought shares.
Read moreSareum granted new patents in China, US
26th Jun 2023 10:54
(Sharecast News) - Clinical-stage biotechnology developer Sareum announced the granting of patents for its lead kinase inhibitors in China and the United States on Monday.
Read moreSareum gets approval for phase one psoriasis studies in Australia
5th May 2023 15:53
(Sharecast News) - Biotechnology developer Sareum Holdings announced on Friday that it has been granted approval by Australia's Therapeutic Goods Administration (TGA) to conduct phase one clinical studies on SDC-1801.
Read moreSareum looks at options as GSK division returns cancer drug candidate
6th Mar 2023 16:16
(Sharecast News) - Biotechnology developer Sareum announced on Monday that GSK subsidiary Sierra Oncology has returned clinical study reports and associated documents related to 'SRA737' to Sareum's co-development partner, the CRT Pioneer Fund.
Read moreSareum confident despite recent setbacks
16th Dec 2022 16:55
(Sharecast News) - Autoimmune and cancer-focussed biotechnology company Sareum said in an update on Friday that it remained "confident" despite some recent setbacks.
Read moreSareum progresses Covid-19 and autoimmune treatment candidate
16th Mar 2022 14:21
(Sharecast News) - Specialist drug developer Sareum Holdings updated the market on the development of its 'SDC-1801' - a potential Covid-19 and autoimmune disease treatment - towards first-in-human trials on Wednesday.
Read moreSareum expects FY losses to widen on higher R&D costs, supply delays
19th Aug 2021 07:41
(Sharecast News) - British drugmaker Sareum said on Thursday that it expects to post a widened full-year loss as a result of increased research-and-development expenditure and delays in compound supply.
Read moreSareum positive on SRA737 outlook after Sierra call
6th Aug 2021 15:00
(Sharecast News) - Specialist drug development company Sareum noted on Friday that Sierra Oncology, the licence holder for the novel Chk1 inhibitor 'SRA737', had discussed its newly-announced global in-licensing agreement with AstraZeneca for AZD5153 with investors, which is a novel BRD4 BET inhibitor, to expand its myelofibrosis pipeline.
Read moreSareum releases 'encouraging' results from Covid-19 research
1st Jul 2021 11:18
(Sharecast News) - Specialist drug development company Sareum announced "encouraging" top-line results from its UKRI grant-funded Covid-19 research project on Thursday.
Read moreSareum's pre-clinical development of SDC-1801 delayed by Covid-19
25th May 2021 10:56
(Sharecast News) - Pharmaceutical company Sareum said on Tuesday that Covid-19 has continued to impact the contract research organisations it was working to complete pre-clinical development of its SDC-1801 drug candidate for autoimmune disease.
Read more